AHSN Network campaign showcases innovators supporting UK economic recovery

Over the past six months, the UK along with the rest of the world has been experiencing unique challenges in terms of business continuity and economic prosperity.

Many businesses are struggling with the changes imposed by the COVID-19 pandemic.

To help demonstrate hope for the future, the AHSN Network and  Academic Health Science Networks (AHSNs) such as Health Innovation Manchester are showcasing some of the many successful companies that have been supported as part of a new campaign.

From the 2019 survey of companies that the AHSNs and the NHS Innovation Accelerator have worked with over the year we found that:

  • £152 million of investment has been leveraged
  • 691 jobs had been created
  • 188 jobs had been safeguarded

Throughout September 2020, AHSNs and the AHSN Network will highlight companies that are doing well, adapting to the new challenges and have the prospect of supporting the UK’s economic recovery in the near future.

To find out more about the companies featured and other innovators the AHSN Network works with visit the AHSN Innovation Exchange website.

Case Study: Intellin - an intelligent remote management diabetes platform

Intellin Diabetes App from Gendius

One of the innovations featured as part of the campaign is the Intellin® intelligent diabetes management platform developed by Gendius. The platform uses clinical data to predict the trajectory of an individual’s diabetes and helps to mitigate progression through smart tips.

Powered by sophisticated AI algorithms, Intellin® is changing the way diabetes is managed. The Intellin® App is today the fastest downloaded diabetes app in the world.

The potential of Intellin® was recognised early by Health Innovation Manchester (HInM) which has supported the developers with bespoke business support, funding for two important projects and important introductions throughout all stages of the innovation.

To date, Intellin® has been downloaded over 300,000 times in 170 countries. A strong academic partnership with the University of Nottingham has grown over several years, and 2020 saw a partnership agreement signed with Astra Zeneca. Intellin will also be launched into the Gulf States in Autumn.

Chris Genders, Co-Founder of Gendius said: “Our engagement with HInM has been invaluable. The support we have received has been multi-faceted, ranging across financial, introductions, advice and belief in what we are doing. Plotting a route into the NHS is one of the hardest challenges any start up faces, and HInM have enabled us to progress far quicker than we could have done without them.”

Daniel Zamora, HInM Commercial Programme Manager, said: “Diabetes is a significant health issue and the Intellin® platform is helping patients manage their diabetes and avoid potential complications. It’s a unique product and we are delighted to have supported the platform through its development. We believe they can reach significant growth both nationally and internationally.”

Read the case study in full on the Innovation Exchange Website

Back to top